GILD vs INCY Stock Comparison

INCY currently leads GILD in this stock comparison, with AIQ scores of 64 vs 46. The clearest difference is quality, while GILD has the stronger momentum profile.

Market data as of Oct 21, 2026 market close· AIQ score gap 18 points
GILD
Healthcare
vs
INCY
Healthcare
GILD
Gilead Sciences, Inc.
Price
$154
Day move
-1.88%
AIQ Score
46/100
Best edge
Momentum
Sector
Healthcare
INCY
Incyte Corporation
Leads
Price
$113
Day move
-2.72%
AIQ Score
64/100
Best edge
Quality
Sector
Healthcare

What is the main difference between GILD and INCY?

INCY leads the current stock comparison as Incyte Corporation, with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Gilead Sciences, Inc. vs Incyte Corporation

Data as of Oct 21, 2026· market close· Healthcare· Coverage 66/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

INCY leads

INCY leads by 18 AIQ points, primarily on Quality and Risk Resilience.

Stable: 5 of 6 evidence groups support INCY, and its signal state is cleanly positive.

Evidence agreement: 5 of 6Comparison trend: Stable
GILD

Gilead Sciences, Inc.

AIQ Score
46/100
AIQ Edge Score
3/10
INCY

Incyte Corporation

Leads
AIQ Score
64/100
AIQ Edge Score
9/10

The Algovestiq AIQ Score currently favors INCY over GILD, 64 versus 46 as of Oct 21, 2026. INCY's advantage is driven primarily by stronger quality and risk resilience, while GILD holds the stronger momentum profile. INCY also shows the weaker technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor INCY today, and the comparison is rated Stable on stability. INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions.

Compare Gilead Sciences, Inc. and Incyte Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

GILD
+176.2%
INCY
+74.7%

Total return comparison

Growth of $10,000, distributions reinvested

GILD $27,618 · INCY $17,470

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare GILD and INCY against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

GILD advantage
0
INCY advantage
  • Quality30 vs 90
    INCY +60
  • Momentum74 vs 40
    GILD +34
  • Risk Resilience46 vs 74
    INCY +28
  • Value37 vs 52
    INCY +15

5 of 6 evidence groups favor INCY. INCY’s edge is concentrated in quality and risk resilience; GILD keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.

GILD+2 AIQ

Largest factor move: Momentum +8

No signal started or stopped since the prior session; its 5 active signals are unchanged.

INCY+3 AIQ

Largest factor move: Momentum +10

New signals

  • MACD Bullish Crossover — bullish, momentum, short horizon

INCY's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — GILD and INCY both carry a full feed there.

The central trade-off

INCY (Incyte Corporation): the stronger current systematic profile, led by quality and risk resilience.

GILD (Gilead Sciences, Inc.): the counter-case, on momentum, technicals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

INCY

INCY on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

INCY

INCY on combined revenue and EPS growth.

Value

INCY

INCY on the peer-relative Value factor, by 15 points.

Momentum

GILD

GILD on the Momentum factor, by 34 points.

Lower downside

INCY

INCY on Risk Resilience, by 28 points.

Analyst upside

INCY

INCY on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureGILDINCYNote
Implied upside to target-2.9%+9.9%INCY has more room
Target dispersion+36.9%+53.7%Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering815Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor INCY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreINCY46 vs 64
FundamentalsINCYrevenue growth 12.1% vs 31.5%; EPS growth -6.2% vs 92.1%; TTM ROE -16.3% vs 29.7%; gross margin 79.6% vs 92.6%; operating margin -4.9% vs 31.6%
ValuationINCYValue 37 vs 52
TechnicalsGILDPrice vs 50-day 4% vs -6.7%; vs 200-day 13.1% vs 8.3%
Risk ResilienceINCYRisk Resilience 46 vs 74
Analyst expectationsINCYTarget upside -2.9% vs 9.9%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of GILD and INCY and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 18 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on INCY.

How the comparison changed

120 daily snapshots · Jun 21 – Oct 20

INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions.

Jun 21GILD leads above the line · INCY leads belowOct 20
Today
INCY +18
46 vs 64
7 sessions ago
INCY +16
45 vs 61
30 sessions ago
INCY +18
46 vs 64
90 sessions ago
INCY +10
55 vs 65

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

GILD

5 bullish / 0 bearish

Only GILD

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • 52-Week High Proximity — bullish, risk, long horizon (1.9%)
  • Uptrend Structure Active — bullish, trend, long horizon
INCY

2 bullish / 0 bearish

No signal that the other name lacks.

Both carry 2 more signals that do not separate them: Golden Cross Active, MACD Bullish Crossover.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

GILDDivergence

Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -1.88%, AIQ +2 points).

INCYDivergence

Price is down while the AIQ Score moved up 3 points over the same session — price and model disagree (price -2.72%, AIQ +3 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1GILD closes the Quality gap — currently 60 points behind, the largest single contributor to INCY's edge.
  2. 2GILD's existing bullish trend signals translate into factor-score gains — the rules are already firing, but the scores have not yet followed.
  3. 3INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

INCY leads on balance
MetricGILDINCY
Revenue growth (YoY)12.1%31.5%
EPS growth (YoY)-6.2%92.1%
Gross margin79.6%92.6%
Operating margin-4.9%31.6%
Return on equity (TTM)-16.3%29.7%
Debt to equity2.220.01

Performance

Split across windows
MetricGILDINCY
1 week (5 sessions)5.8%7.4%
1 month (20 sessions)2.5%-8.1%
3 months (63 sessions)20.1%0.7%
6 months (126 sessions)17.4%21.2%
Year to date26.9%18.1%
1 year (252 sessions)32.8%33.6%

Technicals

GILD has the stronger structure
MetricGILDINCY
RSI (14)61.639.5
ADX (14)23.625.2
Price vs 50-day4%-6.7%
Price vs 200-day13.1%8.3%
Volatility (1M, annualized)26.9%25.4%

Risk

INCY is the more resilient
MetricGILDINCY
Beta0.30.4
Sharpe ratio0.90.91
Sortino ratio1.711.55
Max drawdown-22%-18.3%
Current drawdown-0.6%-10.3%
Annualized volatility26.8%33.4%
Value at risk (95%)-2.5%-2.7%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, GILD or INCY?

On the Algovestiq AIQ Score, INCY is the stronger of the two as of Oct 21, 2026, scoring 64 against GILD's 46. The edge comes from quality and risk resilience. GILD is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is GILD or INCY the better buy right now?

INCY carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor INCY over GILD?

The composite weights Quality, Value, Momentum and Risk Resilience. INCY leads Quality by 60 points; GILD leads Momentum by 34 points; INCY leads Risk Resilience by 28 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, GILD or INCY?

Analyst price targets imply -2.9% upside for GILD and +9.9% for INCY, so the Street currently favors INCY. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, GILD or INCY?

INCY is the better-valued of the two on the peer-relative Value factor. INCY on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, GILD or INCY?

INCY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, GILD or INCY?

GILD on the Momentum factor, by 34 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, GILD or INCY?

INCY is the more resilient of the two, so the other name carries the higher downside risk. INCY on Risk Resilience, by 28 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is GILD more profitable than INCY?

INCY leads on the comparable margin measures — gross margin 79.6% vs 92.6%; operating margin -4.9% vs 31.6%; ttm roe -16.3% vs 29.7%.

Is INCY's lead over GILD getting stronger or weaker?

INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has not changed hands in that window.

What would change the GILD vs INCY verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: GILD closes the Quality gap — currently 60 points behind, the largest single contributor to INCY's edge; GILD's existing bullish trend signals translate into factor-score gains — the rules are already firing, but the scores have not yet followed; INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.

What do the current signals say about GILD and INCY?

GILD: 5 bullish / 0 bearish. INCY: 2 bullish / 0 bearish. The most decision-relevant rule on GILD is Golden Cross Active (bullish, long horizon). On INCY it is Golden Cross Active (bullish, long horizon).

Compare GILD and INCY with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.